Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Finally Wins Arcapta Approval, Having Lost Battle On Desired Dose

This article was originally published in The Pink Sheet Daily

Executive Summary

Bronchodilator is approved for COPD at a 75 mcg dose, compared to 150 mcg and 300 mcg in Europe. Label nods to quality-of-life data.

You may also be interested in...



GSK’s Anoro Ellipta Heads To FDA Panel With Higher Hopes For Higher Dose

The lead LAMA/LABA combination for COPD will be reviewed at the Sept. 10 session of the Pulmonary-Allergy Drugs Advisory Committee.

COPD Market Snapshot: New Products, Limited Differentiation

New drugs are hitting the COPD market, but largely offer incremental benefit over gold standards Advair and Spiriva. Given the modest efficacy improvement and increasingly price sensitive patients and payers, new higher-priced products may find the commercial market a challenge.

Boehringer’s Olodaterol Will Have To Pass LABA Hurdles At January Advisory Committee

Boehringer Ingelheim’s long acting beta-adrenergic agonist for chronic obstructive pulmonary disease will have to overcome LABA class issues in asthma at an advisory committee in January. The drug is up first for single-agent approval, but it is meant to be half of a combination therapy with the blockbuster treatment Spiriva.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel